Questioning the preclinical paradigm: natural, extreme biology as an alternative discovery platform.
Questioning the preclinical paradigm: natural, extreme biology as an alternative discovery platform.
复制标题
DOI：
10.18632/aging.100704
复制
发表时间：
2014-11
期刊：
影响因子：
--
通讯作者：
Corbit KC
中科院分区：
文献类型：
--
作者：
Buffenstein R;Nelson OL;Corbit KC
科学继续发展的速度是惊人的。从宇宙学、微处理器、结构工程到DNA测序，我们的生活不断受到以科学为基础的技术的影响。然而，治疗人类疾病的进展，特别是与年龄有关的疾病，如癌症和阿尔茨海默病，相对缓慢。考虑到投资额并不低得不成比例，人们不禁要问，为什么我们对开发治疗这种严重疾病的有效药物的希望令人沮丧地没有实现。在这里，我们讨论了药物开发的一个方面-啮齿动物模型-并提出了一种替代方法，发现研究植根于进化实验。我们的目标是加快围绕我们如何才能走向更多的翻译临床前工作的对话。
The pace at which science continues to advance is astonishing. From cosmology, microprocessors, structural engineering, and DNA sequencing our lives are continually affected by science-based technology. However, progress in treating human ailments, especially age-related conditions such as cancer and Alzheimer's disease, moves at a relative snail's pace. Given that the amount of investment is not disproportionately low, one has to question why our hopes for the development of efficacious drugs for such grievous illnesses have been frustratingly unrealized. Here we discuss one aspect of drug development –rodent models – and propose an alternative approach to discovery research rooted in evolutionary experimentation. Our goal is to accelerate the conversation around how we can move towards more translative preclinical work.